COMP <GO>
XBIO vs APUS // EV/EBITDA & P/E VALUATION
Xenetic Biosciences Inc. (NASDAQ) VS. Apimeds Pharmaceuticals US Inc. (NYSE) • 15-METRIC TALLY: XBIO 3
— APUS 1
■ METRIC PARITY
LAST: $2.12 (+0.95%) • MKT CAP: $5.0M
valuation
—
LAST: $3.21 (+4.56%) • MKT CAP: $5.0M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (XBIO VS. APUS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | XBIO | APUS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -30.30% | -6.20% | -24.10 | APUS | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 19.00% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 1/9 | +3.00 | XBIO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.5 | 42.4 | +1.11 | XBIO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.0M | $5.0M | $15.7K | XBIO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | XBIO REV | APUS REV | XBIO GROSS % | APUS GROSS % | XBIO FCF | APUS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.0M | $0 | — | — | -$2.3M | -$9.0M |
| FY 2024 | $2.5M | $0 | — | — | -$2.8M | -$733.5K |
| FY 2023 | $2.5M | $0 | — | — | -$4.1M | -$627.8K |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
XBIO // BETA —
APUS // BETA —